⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
SYRE
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
globenewswire.com
SYRE
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
globenewswire.com
SYRE
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
globenewswire.com
SYRE
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
globenewswire.com
SYRE
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
globenewswire.com
SYRE